Saturday, February 25, 2023 7:03:52 AM
NWBO could have chose to go the route of their own mfg capabilities even though that would have been the less ideal route to an existing, established CDMO, but they decided why not fund it so the CEO can build and own the CDMO from scratch. And like you said at the expense of the shareholder. Nice!
Complete response letters (CRL) can happen for various reasons including manufacturing. I'm not sure at this point in NWBO's financial state, they can survive a CRL given that they are living foot to mouth. Not saying it will happen, but that is the state of their finances. And if you have been investing in biotechs long enough, you know nothing is guaranteed in regulatory approvals even with clean data.
And 100% there are better companies that inform their shareholders and meet their timelines. Hopefully, UK submission is near and you can get out with some profit and still keep your sanity!
Complete response letters (CRL) can happen for various reasons including manufacturing. I'm not sure at this point in NWBO's financial state, they can survive a CRL given that they are living foot to mouth. Not saying it will happen, but that is the state of their finances. And if you have been investing in biotechs long enough, you know nothing is guaranteed in regulatory approvals even with clean data.
And 100% there are better companies that inform their shareholders and meet their timelines. Hopefully, UK submission is near and you can get out with some profit and still keep your sanity!
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
